リキディア・テクノロジーズ
Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.60 | $133M | $50M |
| 2025 Q4 | 0.17 | $92M | $42M |
| 2025 Q3 | -0.04 | $54M | -$11M |
| 2025 Q2 | -0.49 | $9M | -$41M |
| 2025 Q1 | -0.45 | $3M | -$31M |
| 2024 Q4 | -0.45 | $3M | -$26M |
| 2024 Q3 |
| -0.30 |
| $4M |
| -$27M |
| 2024 Q2 | -0.37 | $4M | -$24M |